#USA #ZIIHERA #Dublin #Jazz Pharmaceuticals #Xywav

Jazz Pharmaceuticals Q3 2026 Financial Highlights

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) recently disclosed its financial results for the third quarter of 2026 (Q3 2026), showcasing a robust revenue performance that underscores the company's ongoing commitment to growth and innovation in the biopharma sector. The company achieved total revenues of $1.2 billion, marking a remarkable 10% increase year-over-year. This strong financial outcome prompted Jazz Pharmaceuticals to raise its full-year revenue guidance for 2026 to a range of $4.775 to $4.85 billion.

Key Drivers of Growth

Renee Gala, the President and CEO of Jazz Pharmaceuticals, emphasized that the company’s strong third-quarter results are a reflection of sustained business execution. She stated, “Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance.” This growth momentum has been driven by several key developments, including the launch of Ziihera, a potent treatment recently approved by the FDA for first-line HER2-positive gastroesophageal adenocarcinoma (GEA), and the acquisition of Actio Biosciences Inc., which enhances the company's epilepsy treatment portfolio.

Significant Product Portfolio Updates

1. Ziihera Launch: Jazz Pharmaceuticals launched Ziihera-based combinations with high demand observed in its first month, achieving a notable average demand increase. The HERIZON-GEA-01 trial results presented at the European Society for Medical Oncology Congress 2026 demonstrated a sustained survival benefit, reinforcing Ziihera's potential as a standard-of-care therapy.

2. Xywav Growth: The Xywav product, an oral solution, saw net sales rise by 12% year-over-year, yielding $483 million in Q3 2026. Approximately 425 new patients were added during the quarter, showcasing strong market demand among patients with narcolepsy and idiopathic hypersomnia.

3. Actio Acquisition: The recent acquisition of Actio, with the addition of ABS-1230 (JZP6979) to its rare epilepsy portfolio, positions Jazz to introduce a first-in-class precision therapy aimed at KCNT1-related epilepsy. This innovative treatment is currently in an ongoing Phase 1b/2a trial.

Operational Efficiency and Future Guidance

In addition to impressive revenue growth, Jazz Pharmaceuticals generated $1.3 billion in cash from operations during the first nine months of 2026, showcasing a disciplined operational approach. The company also completed a strategic financial maneuver, issuing $1.25 billion of exchangeable senior notes while repurchasing $225 million of ordinary shares.

The company's operating expenses reflect a shift in the financial landscape due to the inclusion of acquired in-process research and development (IPRD) costs related to the Actio acquisition. Notably, IPRD expenses have influenced both GAAP and non-GAAP earnings measures for the quarter.

Financial Overview

In terms of financial statistics, Jazz Pharmaceuticals reported:

• - GAAP net loss of $(483.4) million or $(7.48) per share in Q3 2026, which includes significant R&D expenses related to acquisitions.
• - Non-GAAP adjusted net loss of $(250.8) million or $(3.88) per share, highlighting the impact of IPRD expenses.

Future Outlook

With a robust pipeline of products and a commitment to innovating therapeutics in rare diseases, Jazz Pharmaceuticals is poised for significant impacts in the healthcare landscape. The company anticipates continuing to build on its momentum, further enhancing shareholder value and transforming patient lives through its targeted treatment offerings. Future product launches and potential regulatory approvals could enhance Jazz’s market position even further.

As a leader in the field, Jazz Pharmaceuticals continues to prioritize the needs of patients while maintaining strategic growth initiatives. The investor community should remain attentive to the promising developments coming from this dynamic biopharma company in the months ahead.